Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares 10 20 Year Treasury Bond ETF (TLH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

iShares 10 20 Year Treasury Bond ETFTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

iShares 10 20 Year Treasury Bond ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares 10 20 Year Treasury Bond ETF trades at $96.55, while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

TLHVRTX
Sector
Fixed IncomeHealth
52-Week High
$105.36$529.65
52-Week Low
$96.39$376.62
Market Cap
$134.25B
Enterprise Value
$128.37B

Returns comparison

Trailing returns across standard periods

About iShares 10 20 Year Treasury Bond ETF

TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.

Read more on TLH

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX